William K. Oh, Kevin Proctor, Mari Nakabayashi, Carolyn Evan, Lauren K. Tormey, and Timothy Daskivich are employees of Dana-Farber Cancer Institute, which has received research funds from Analysis Group, Inc.
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid†
Version of Record online: 20 FEB 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 6, pages 1090–1096, 15 March 2007
How to Cite
Oh, W. K., Proctor, K., Nakabayashi, M., Evan, C., Tormey, L. K., Daskivich, T., Antràs, L., Smith, M., Neary, M. P. and Duh, M. S. (2007), The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer, 109: 1090–1096. doi: 10.1002/cncr.22504
Sponsored by F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
- Issue online: 7 MAR 2007
- Version of Record online: 20 FEB 2007
- Manuscript Accepted: 6 DEC 2006
- Manuscript Revised: 23 NOV 2006
- Manuscript Received: 19 SEP 2006
- renal impairment;
- hormone-refractory prostate cancer;
- zoledronic acid;
- risk factors
Bisphosphonates have been used to treat bone metastases in hormone-refractory prostate cancer (HRPC), but certain agents have been associated with renal toxicity. For this observational study, the authors assessed the risk of renal impairment in patients with HRPC who received zoledronic acid from December 1999 to April 2005.
A comprehensive medical records review was performed in a major tertiary oncology center (n = 122 patients). The primary outcome of renal impairment was defined as an increase ≥0.5 mg/dL or ≥1.0 mg/dL over baseline creatinine value if the baseline value was <1.4 mg/dL or ≥1.4 mg/dL, respectively. A risk factor analysis was conducted using the Andersen-Gill extension to the Cox proportional hazards model.
Renal impairment was observed in 23.8% of patients. The risk of renal impairment increased with an extended duration of zoledronic acid therapy (<6 months, 11.1%; ≥24 months, 26.3%) and previous pamidronate treatment (45.5% vs 19.0% for patients with no prior pamidronate). A significantly greater risk of renal impairment was associated with increasing age at zoledronic acid initiation, prior pamidronate use, and a history of renal disease, hypertension, or smoking (P ≤ 0.05).
In an outpatient clinic setting, the risk of renal impairment among patients with HRPC who received zoledronic acid was greater than the risk reported previously in clinical trials. Cancer 2007 © 2007 American Cancer Society.